Bremelanotide · 10 mg / vial- ·3 mL bacteriostatic water
- ·10 × 1 mL insulin syringes
- ·Alcohol swabs
PT-141 10 mg
Approved MC3R/MC4R agonist — cyclic heptapeptide.
PT-141 is bremelanotide — an approved cyclic heptapeptide MC3R/MC4R agonist. The research-grade form is commonly used in receptor-binding and signalling assays.
What the peptide is.
PT-141 (bremelanotide) was developed from MT-II and optimised for melanocortin-4 receptor activity while retaining MC3R activity. It is a cyclic seven-residue peptide with enhanced metabolic stability.
FDA approved for hypoactive sexual desire disorder (HSDD) in premenopausal women in 2019 under the brand name Vyleesi®. Omega Grade supplies lyophilised research-grade peptide for in vitro laboratory work, not the clinical formulation.
Non-selective agonism at MC3R and MC4R; weaker MC1R activity relative to MT-II. Central nervous system penetration; downstream signalling through cAMP / PKA.
Reconstitution, storage, and handling.
Lab-technical guidance for the researcher handling the material. Not therapeutic dosing, not administration guidance — those are not within the scope of this supply.
- Recommended solvent
- Bacteriostatic water for injection (0.9% benzyl alcohol) — included with kit
- Typical volume
- 1 – 2 mL
- Inject diluent slowly down the side of the vial onto the cake.
- Swirl gently — do not shake.
- Solution should be clear and colourless. Discard if not.
- Lyophilised
- −20 °C, desiccated, protected from light. Stable at 15–25 °C for up to 30 days in transit.
- Reconstituted
- 2–8 °C, original vial, consumed within 4 weeks.
- Shelf life · sealed
- 24 months from date of manufacture when stored lyophilised at −20 °C.
- Shelf life · reconstituted
- Up to 4 weeks refrigerated.
- ▸Standard peptide handling.
This lot, documented.
Every shipment is accompanied by a signed four-page analytical report including the HPLC chromatogram, ESI-MS spectrum, purity calculation, and sample handling chain-of-custody.
The report you will receive is specific to the lot dispatched to you. The display below is a current representative example.
04:22:11▸lot 26-04-A received ┈ 5.00 g04:22:40▸weight check ┈ PASS ±0.4 mg04:23:12▸sample → janoshik ┈ 50 mg04:23:12▸tracking #jnk-921833405:18:03▸HPLC result ┈ 99.24 %05:18:04▸MS obs 4729.42 Da ┈ PASS05:18:05▸coa.pdf signed ┈ attached05:18:06▸lot approved ┈ LIVE
REPORT ID JA-26-04-012
SUBJECT PT-141 10 mg
DESIGNATION Bremelanotide
LOT 26-04-A
METHOD RP-HPLC, ESI-MS
COLUMN C18, 250 x 4.6 mm, 5 um
MOBILE PHASE A: 0.1% TFA in H2O
B: 0.1% TFA in ACN
GRADIENT 5 -> 65% B over 20 min
FLOW RATE 1.0 mL/min
DETECTION UV 214 nm
INJECTION 20 uL @ 0.5 mg/mL
---
PURITY (A%) 99.00
MASS EXP. 1025.19 Da
MASS OBS. 1025.21 Da
---
CONCLUSION Identity CONFIRMED · Purity PASS
SIGNED BY J. Novak, MSc · Janoshik Analytical SVK
DATE 2026-04-11Research references for PT-141 10 mg.
2 peer-reviewed publications. Links resolve to PubMed. DOIs are provided where available.
- [01]Kingsberg SA, Clayton AH, Portman D, et al.
Bremelanotide for Hypoactive Sexual Desire Disorder (RECONNECT)
Obstetrics & Gynecology · 2019 - [02]Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB
Double-blind, placebo-controlled evaluation of PT-141 nasal spray in men with ED
International Journal of Impotence Research · 2004
- Q.How is this different from Vyleesi®?
- A.The active peptide is the same (bremelanotide). Vyleesi® is a sterile pre-filled autoinjector for therapeutic use; Omega Grade supplies lyophilised research peptide for laboratory investigation only.
This peptide is supplied by Omega Grade for in vitro laboratory research use. It is not a drug, food, cosmetic, or dietary supplement. It is not approved by the FDA, EMA, MHRA, PMDA, or any other regulatory authority for any therapeutic indication.
No claim of therapeutic benefit is made or implied. The material is not intended for human or veterinary consumption, administration, or any form of self-experimentation. By purchasing, you acknowledge the researcher terms and accept full responsibility for local import compliance and all handling.
